

DOCKET NO.: CP380F (CEPH-3138)
Application No.: 10/776,504
Office Action Dated: June 2, 2006

PATENT

RECEIVED
CENTRAL FAX CENTER

NOV 01 2006

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A method of treating ~~cancer~~ acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, or acute erythroleukemia in a human, which comprises administering to the human a combination of (i) a therapeutically effective amount of ~~one or more arsenic compounds~~ trioxide, and (ii) all-trans retinoic acid.
2. (Canceled)
3. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the arsenic trioxide is formulated as an ionic aqueous solution.
4. (Currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 10 µg to about 200 mg.
5. (Currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 0.5 mg to about 150 mg.
6. (Currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ trioxide is from about 0.5 mg to about 70 mg.
7. (Currently amended) The method of claim 1, wherein the arsenic ~~compound~~ trioxide is administered parenterally.
8. (Currently amended) The method of claim 1, wherein the arsenic ~~compound~~ trioxide and the all-trans retinoic acid are administered intravenously.
9. (Currently amended) The method of claim 1, wherein the all-trans retinoic acid and the arsenic ~~compound~~ trioxide are administered in combination with an effective amount of at least one further therapeutic agent.

Page 3 of 10

BEST AVAILABLE COPY

DOCKET NO.: CP380F (CEPH-3138)

PATENT

Application No.: 10/776,504

Office Action Dated: June 2, 2006

10. (Original) The method of claim 9, wherein the further therapeutic agent is a chemotherapeutic or radiotherapeutic.
11. (Currently amended) The method of claim 9, wherein the further therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, ~~all-trans retinoic acid~~, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.
12. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the dose is varied according to the body weight of the human.
- 13-18. (Canceled)
19. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the cancer has metastasized.
20. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the all-trans retinoic acid is administered prior to the arsenic trioxide.
21. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the all-trans retinoic acid is administered after the arsenic trioxide.
22. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the all-trans retinoic acid and the arsenic trioxide are administered concurrently.
23. (Canceled)
24. (Currently amended) The method of ~~claim 2~~ claim 1, wherein the cancer is refractory.